Crescendo Raises $70m In Largest European Biotech Series B Of Year

 
• By Lucie Ellis-Taitt

Crescendo Biologics raises $70m to take its first Humabody asset into clinical trials for prostate cancer; the company’s CEO Peter Pack tells Scrip more about its diverse financiers and plans for big pharma partnering in the future.

Peter Pack
Peter Pack, CEO of Crescendo Biologics • Source: Lucie Ellis

UK-based Crescendo Biologics Ltd. has raised $70m (€57m) through a series B financing to progress its lead program CB307 into clinical studies – marking the largest European series B financing of 2018 so far.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business